Dr. Sarita Rao Best Cardiologist

  Background The burden of heart failure (HF) with preserved ejection fraction (EF) is increasing in India. Compared with Western populations, Indian patients often present at a younger age with a high burden of diabetes, chronic kidney disease, central adiposity, anemia, chronic obstructive airway disease, peripheral artery disease, and ischemic heart disease. These differences pose challenges for the implementation of existing EF-based management strategies and support the need for India-specific guidance. Objectives The objectives of this study were to develop India-specific consensus recommendations for the diagnosis, phenotypic assessment, and management of HF with preserved EF (HFpEF) across diverse healthcare settings. Methodology A modified Delphi consensus process involving 25 HF experts from India and Europe was used to formulate recommendations based on a review of contemporary evidence and structured expert voting. Results Consensus was achieved on recommendations cover...

 The cardiovascular continuum is the developmental process of cardiovascular diseases (CVDs) leading to heart failure (HF) and sudden cardiac death. Beta-blockers (BBs) are at the forefront of managing conditions along this continuum, ranging from cardiovascular (CV) risk factors to heart failure. In particular, bisoprolol proved to be a highly cardio-selective BB with a favourable pharmacokinetic profile, demonstrating long-term safety, good tolerability, and proven efficacy in reducing cardiac events, including arrhythmias and mortality in patients with heart failure with reduced ejection fraction (HFrEF). This evidence-based and perspective showcased numerous clinical studies revealing the utility of bisoprolol in managing patients with CVDs, particularly HFrEF and stable angina. It also included safety evidence for bisoprolol in patients with renal and hepatic dysfunction, etc. Expert opinions from leading cardiologists across India further reinforce the role of bisoprolol as a...